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1. Introduction 
An adrenal incidentaloma is an important clinical finding that is often considered harmless, 
but can be the tip of the iceberg. The term incidentaloma indicates an adrenal mass larger 
than 1 cm, incidentally discovered during imaging studies performed for reasons other than 
suspicion of adrenal pathology. Lesions identified during staging procedure or work-up for 
patients with a known extra-adrenal malignancy are not considered to be an incidentaloma 
(Young, Jr. 2000; Grumbach et al. 2003; Young, Jr. 2007; Singh & Buch 2008; Terzolo et al. 
2009; Androulakis et al. 2011).   
The entity incidentaloma is not a new finding and has been reported for many years 
(Grumbach et al. 2003; Young, Jr. 2007; Singh & Buch 2008; Terzolo et al. 2009; Androulakis 
et al. 2011). Because of the increased use of imaging techniques and improvement in 
abdominal imaging, the frequency of incidentaloma findings is increasing as well. Recent 
studies using high-resolution computed tomography (CT) have reported an estimated 
prevalence of 4% (Young, Jr. 2007; Singh & Buch 2008). In autopsy studies the prevalence 
ranged 0.2%-8.7%, depending on definitions used and age group, as there is an age-
dependent occurrence of adrenal incidentalomas (Young, Jr. 2000; Grumbach et al. 2003; 
Young, Jr. 2007; Singh & Buch 2008; Terzolo et al. 2009; Androulakis et al. 2011). The 
estimated prevalence in patients younger than 30 years is < 1%, in contrast to a 7% 
frequency in patients 70 years of age or older (Young, Jr. 2007). With an aging population 
and advanced radiological techniques becoming more widely available, the increasing 
frequency of adrenal incidentalomas is of growing importance. 
When an incidentaloma is found, it is of vital importance to make an early and reliable 
differentiation between benign and (potentially) malignant lesions, but also to assess tumor 
functionality. The mass can originate from either the adrenal medulla or cortex 
(Androulakis et al. 2011). Consequently, a spectrum of different pathological conditions may 
underlie an incidentaloma, all requiring a different therapeutic approach. As much as 38 
different diagnoses have been reported in patients with a serendipitous discovered adrenal 
tumor (Young, Jr. 2000). Most adrenal incidentalomas are clinically nonhypersecretory 
benign adenomas, with an estimated frequency of 70-80%, which cause no health problems. 
However, in 5-20% of patients who have no endocrinological signs or symptoms, analysis 
reveals subclinical hypercortisolism (Grumbach et al. 2003; Young, Jr. 2007; Singh & Buch 
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2008; Terzolo et al. 2009). Other frequently reported diagnoses besides a nonfunctioning 
adenoma include adrenocortical carcinoma (ACC), pheochromocytoma, metastasis and 
aldosterone-producing adenoma. Although malignancy is rare, it is of great clinical concern 
because of the poor prognosis (Grumbach et al. 2003; Terzolo et al. 2009). 
After recognition of an incidentaloma both patient and physician are faced with 
uncertainties regarding the course, likelihood of a malignancy and treatment of the 
adrenal mass. Unfortunately, no diagnostic or therapeutic strategy has been validated in 
prospective clinical trials. Thus, the diagnostic work-up as well as management of an 
incidentaloma is a growing public health challenge (Young, Jr. 2007; Singh & Buch 2008; 
Terzolo et al. 2009).  
The goal of this chapter is to provide a diagnostic guideline, which contains information about 
clinical presentation, biochemical work-up and radiological imaging. In addition, this chapter 
offers practical recommendations for the management of adrenal incidentaloma, including 
surgery and follow-up. Also, therapeutic options for adrenal carcinoma are discussed. 
Furthermore, we present organisational recommendations concerning the management of 
adrenal incidentaloma and emphasize the need for centralization of adrenal disease-research 
and patient care. This will provide patients with an opportunity to receive optimal care, as the 
beneficial effects of specialization have been proven multiple times in other rare diseases.   
2. Diagnostics of incidentaloma 
The first step in the evaluation of adrenal incidentalomas is establishing the definition of the 
tumor type, beginning with a thorough history taking and extensive physical examination, 
with attention to signs or symptoms of hormonal overproduction, a malignancy or 
pheochromocytoma. Furthermore, hormonal work-up and radiological imaging is required 
in the diagnostic evaluation of the adrenal mass.  
2.1 History and physical examination 
2.1.1 History 
Signs suggestive of hormonal overproduction may include Cushing’s characteristics, 
symptoms of hyperaldosteronism or sex hormone excess. Cushing’s syndrome may be 
asymptomatic in the event of subclinical disease or present with weight gain and central 
obesity, flushes, proximal muscle weakness, and polydipsia. Furthermore, cognitive 
changes, such as irritability, depression or restlessness, may also be present. Hirsutism, 
acne, gynaecomastia and oligomenorrhoe may be symptoms of hypercortisolism or sex 
hormone overproduction. Features of primary hyperaldosteronism are nocturia, muscle 
cramps and polyuria in case of hypokalaemia and palpitations (Young, Jr. 2007; Singh & 
Buch 2008; Androulakis et al. 2011). 
The classic triad of symptoms associated with a pheochromocytoma includes episodic 
headaches of variable duration, tachycardia and generalized sweating. However, this 
combination of symptoms is present in only a small percentage of patients (10%) (Nieman 
2010). Characteristics less commonly present are pallor, dyspnea and anxiety and secondary, 
complaints of hyperglycemia, unintentional weight loss, arrhythmias and cardiomyopathy 
(Young, Jr. 2007; Androulakis et al. 2011). 
An adrenocortical carcinoma may either present with signs of adrenal hypersecretion as 
mentioned above or symptoms related to mass effect, such as abdominal fullness or 
abdominal pain. Cancer-related signs (e.g. fever, unintentional weight loss) are less 
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frequently present (Young, Jr. 2007; Singh & Buch 2008; Terzolo et al. 2009; Androulakis et 
al. 2011). 
2.1.2 Physical examination  
Clinical features of Cushing’s syndrome detected during physical examination are 
hypertension, central obesity, striae, facial rounding (‘moon face’), supraclavicular and 
dorsocervical fat pads (‘buffalo hump’), proximal muscle weakness, clitoris hypertrophy, acne 
and hirsutism. Primary aldosteronism is characterized by hypertension. In rare cases, female 
patients can present with signs of virilization (e.g. acne, hirsutism) as a result of testosterone 
excess. In contrast, an estrogen secreting adrenal lesion can produce signs of feminization, 
such as gynaecomasty in the male patient. A pheochromocytoma may present with 
hypertension (paroxysmal or sustained), orthostatic hypotension, pallor and sweating on 
physical examination. Adrenocortical carcinoma may as well present signs of hormonal 
overproduction mentioned above. In addition, a palpable mass may be present at abdominal 
examination (Young, Jr. 2007; Singh & Buch 2008; Terzolo et al. 2009; Androulakis et al. 2011).  
 
Causes 
Estimated 
prevalence 
Clinical presentation  
Adenoma    
Subclinical Cushing’s 
Syndrome 
9 % 
Weight gain with central obesity, flushes, 
proximal muscle weakness, polydipsia, cognitive 
changes 
Primary aldosteronism 1.2 % Nocturia, muscle cramps, polyuria, palpitations 
Androgen 
overproduction 
Rare Hirsutism, acne, oligomenorrhoe 
Nonfunctioning 73.9 % - 
Pheochromocytoma 4.7 % 
Episodic headaches, tachycardia, generalized 
sweating, pallor, dyspnea, anxiety 
Malignancy    
Adrenocortical 
carcinoma 
4.8 % 
Symptoms of functioning mass (see above), 
abdominal pain or fullness 
Metastasis  2.3 % 
Cancer-related symptoms (fever, unintentional 
weight loss)  
Table 1. Prevalence and clinical presentation of the most frequent types of adrenal 
incidentaloma (Young, Jr. 2007, Singh and Buch 2008)  
2.2 Hormonal evaluation 
Additional hormonal work-up is necessary in the evaluation of tumor functionality. Although 
an adrenal mass may appear clinically nonhypersecretory, up to 20% of patients with an 
incidentaloma may have hormonal dysfunction, which might be associated with a higher risk 
of morbidity, such as metabolic disorders and cardiovascular disease (Singh & Buch 2008; 
Androulakis et al. 2011). 
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2.2.1 Subclinical Cushing’s Syndrome 
The most frequently diagnosed endocrine alteration in patients with an incidentaloma is 
Subclinical Cushing’s Syndrome (SCS), which refers to autonomous and dysregulated 
cortisol secretion by the tumor, which may cause mild cortisol excess without typical 
signs and symptoms of hypercortisolism (Young, Jr. 2007; Singh & Buch 2008; 
Androulakis et al. 2011). It is also known as subclinical autonomous glucocorticoid 
hypersecretion (Grumbach et al. 2003). The average prevalence is 9% (range 1-29%, 
depending on criteria used)(Singh and Buch 2008). It is difficult to characterize, since 
clinical Cushing’s syndrome is not present and patients may have normal 24-hour 
urinary free cortisol secretion (Terzolo et al. 2009). Therefore, late-night salivary cortisol 
and/or overnight dexamethasone (1 mg) suppression test is recommended to detect 
subclinical hypercortisolism (Grumbach et al. 2003; Nieman 2010). The optimal cut-off 
value is much discussed. A cortisol value greater than 138 nmol per liter (5 microg/dL) 
in response to 1mg dexamethasone overnight is associated with glucocorticoid 
overproduction and has an estimated sensitivity of 98% and specificity of 80-98% (Singh 
and Buch 2008). When a level between 50-70 nmol/L (1.8-2.5 microg/dL) is used as cut-
off value, confirmatory testing is indicated, such as midnight plasma cortisol or serum 
ACTH level (Grumbach et al. 2003; Young, Jr. 2007; Singh & Buch 2008; Terzolo et al. 
2009).  
Recent studies and own observations identify urinary steroid profiling as a very 
promising screening instrument for early differentiation between benign and malignant 
tumors. A quantitative analysis of steroid precursors by gas chromatography and mass 
spectrometry reveals steroid patterns associated with particular clinical problems. A 
recently designed algorithm screens for nine metabolites in a 24-hour urine sample and 
has impressive test characteristics with high sensitivity and specificity (Taylor A & Arlt 
2010).  
2.2.2 Primary aldosteronism 
Primary aldosteronism (Conn’s syndrome) is present in approximately 1.2% of patients 
with an adrenal incidentaloma (Androulakis et al. 2011). The textbook presentation 
comprises hypertension and hypokalaemia, however almost 40% of patients are 
normokalaemic (Young, Jr. 2000; Singh & Buch 2008). Therefore, serum potassium level is 
not considered a reliable screening method. Hormonal work-up includes routine 
measurement of ambulatory morning plasma aldosterone concentration to plasma renin 
activity ratio (PAC/PRA ratio) in hypertensive patients. This can be performed during 
treatment with antihypertensive drugs with the exception of beta blockers and 
aldosterone antagonists. A PAC/PRA ratio ≥ 30 and plasma aldosterone concentration 
greater than 0.5 nmol/L is indicative of autonomous aldosterone secretion. Since the 
PAC/PRA ratio is influenced by time of sampling and posture of the patient, the 
diagnosis needs to be confirmed by additional measurement of mineralocorticoid 
secretory autonomy (e.g. saline infusion test) (Young, Jr. 2000; Grumbach et al. 2003; 
Young, Jr. 2007; Singh & Buch 2008; Nieman 2010). 
2.2.3 Sex hormone overproduction 
Sex hormone-secreting adrenal tumors rarely present as an incidentaloma, since they are 
usually symptomatic (e.g. hirsutism, virilization, gynaecomasty). Androgen overproduction 
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may be a feature of ACC, but measurement of androgens and their precursors in serum has 
a low diagnostic accuracy in differentiating malignant from benign adrenal masses. Routine 
measurement of androgen or estrogen production is not necessary in patients with an 
incidentaloma (Young, Jr. 2000; Young, Jr. 2007) 
Nonclassical congenital adrenal hyperplasia may cause unilateral or bilateral adrenal 
lesions and is an uncommon cause (< 1%) of incidentalomas. Routine cosyntropin-
stimulation testing with measurement of cortisol precursors is not warranted, unless the 
diagnosis is suspected based on clinical manifestation (hirsutism, acne, menstrual 
irregularities) or the presence of bilateral adrenal masses (Young, Jr. 2000; Young, Jr. 2007; 
Nieman 2010). 
2.2.4 Silent pheochromocytoma 
The estimated prevalence of a pheochromocytoma among patients with an adrenal 
incidentaloma is 4-7% Although it is mostly a benign condition, it may cause significant 
morbidity and mortality. Hypertension is constantly present in only half of the patients and 
paroxysmal in approximately 30%. It is essential to diagnose a catecholamine-secreting 
pheochromocytoma, since it has the potential to cause cardiac arrhythmias and 
hemodynamic instability even in asymptomatic patients. Therefore, routine measurement of 
fractionated metanephrines and catecholamines in 24-hour urine specimen is indicated in all 
patients presenting with an incidentaloma. Recent research reported the superiority of 
determination of fractionated plasma free metanaphrines, with a diagnostic sensitivity of 
99% and specificity of 89%. However, this method is not widely available (Grumbach et al. 
2003; Young, Jr. 2007; Singh & Buch 2008; Terzolo et al. 2009; Nieman 2010; Androulakis et 
al. 2011).  
2.3 Radiologic evaluation  
Imaging studies that brought the incidentaloma to light should be reviewed with a focus on 
the adrenal glands, but will often be insufficient. The goal is to distinguish adenomas from 
malignant masses. Several imaging characteristics are used to assess the malignant potential 
and to provide information concerning appropriate management.  
2.3.1 Computed Tomography  
It is advised to perform an unenhanced CT-scan to help distinguish adenomas from 
nonadenomas, followed by a delayed contrast-enhanced sequence and computed wash-out 
percentage (Hamrahian et al. 2005).  Attenuation of adrenal masses is measured in 
Hounsfield Units. A low attenuation on CT before contrast administration indicates high 
lipid content and is found in adenomas. However, around 30% (range 10-40%) of adenomas 
do not have a large lipid content and consequently may be difficult to discriminate from 
nonadenomas. 
Furthermore, size and appearance of the adrenal lesion may as well help to differentiate 
between benign and malignant tumors. The probability of an incidentaloma being an 
ACC is directly related to size of the lesion. A diameter greater than 4 cm is reported to 
have 90% sensitivity for identifying ACC, but a low specificity, since only approximately 
25% of lesions greater than 4 cm are malignant. In addition, calcifications, necrosis and 
hemorrhage are indicative of a malignancy (Young, Jr. 2000; Terzolo et al. 2009; Nieman 
2010).   
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CT-
characteristic  
Adenoma  
Pheochromocy
toma 
Adrenocortical 
carcinoma 
Metastasis  
Size Usually < 4 cm 
Large, usually 
> 3 cm 
Large, usually 
> 3 cm 
Variable, 
usually < 3 cm 
Shape  
Round, smooth 
margins 
Round, smooth 
margins 
Irregular, 
unclear 
margins 
Oval, irregular 
margins 
Attenuation on 
unenhanced CT 
< 10 HU > 10 HU  > 10 HU > 10 HU  
Washout (in 10 
minutes) 
Rapid, > 50%  Delayed, < 50% Delayed, < 50% Delayed, < 50% 
Growth rate Stable  Slow (usually) Rapid (usually) Variable  
Other features 
Rarely 
necrosis, 
hemorrhage or 
calcification 
Hemorrhage, 
cystic necrotic 
areas 
Necrosis, 
hemorrhage, 
calcification 
Hemorrhage, 
cystic necrotic 
areas 
HU = Hounsfield Units 
Table 2. CT characteristics of the most frequent types of an incidentaloma (Young, Jr. 2000; 
Young, Jr. 2007; Terzolo et al. 2009) 
2.3.2 Magnetic Resonance Imaging 
Magnetic Resonance Imaging (MRI) is equally effective as CT in differentiating benign from 
malignant adrenal masses  (Grumbach et al. 2003). A normal adrenal gland is characterized 
by an equal or slightly lower intensity than that of the liver on T1 and T2. In contrast, 
malignant lesions are hyperintense on T2-weighted images (Young, Jr. 2000; Androulakis et 
al. 2011).  
2.3.3 Positron Emission Tomography 
Additional advanced radiological testing is generally not indicated. 18-Fluoro-2-deoxy-D-
glucose positron emission tomography (PET) is highly sensitive in identifying malignant 
lesions. However, it is of limited use regarding the evaluation of adrenal incidentaloma (in 
patients without a prior history of malignancy) (Young, Jr. 2007; Singh & Buch 2008; Boland 
2011)  
2.4 Fine-Needle Aspiration 
There is no evidence to support the routine use of computed tomography-guided fine-
needle aspiration (FNA) in the diagnostic evaluation of an incidentaloma. It is rarely 
informative, since it has a high-false negative rate, and there is a risk of complications, such 
as hemorrhage, abdominal pain, pancreatitis and pneumothorax. Moreover, its added value 
over radiological imaging has not been established. In case of a suspected 
pheochromocytoma FNA is contraindicated, since manipulation of the tumor can 
potentially cause a hypertensive crisis. Furthermore, biopsy of an adrenocortical carcinoma 
may lead to tumourspill and consequently tumor recurrence along the needle track. The 
only role of FNA in the evaluation of an incidentaloma is in confirming metastatic disease in 
patients with a known extra-adrenal malignancy without other signs of metastases (Young, 
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Jr. 2000; Grumbach et al. 2003; Young, Jr. 2007; Quayle et al. 2007; Singh & Buch 2008; 
Terzolo et al. 2009; Nieman 2010).  
3. Diagnostic evaluation 
The work-up leads to a preliminary conclusion which determines further management. The 
spectrum varies from benign adenoma to the presumption of malignancy or a 
pheochromocytoma.  
3.1 Suspect adenoma 
As noted before, the first step in evaluation of an adrenal incidentaloma is discrimination 
between a benign or malignant adrenal mass, in which radiological imaging by CT-scan has 
a fundamental role. Most adrenal incidentalomas exhibit characteristic features of 
adrenocortical adenoma (ACA). Adenomas typically present as small (< 4 cm) lesions, with 
clear margins and high lipid content, which is characterized by low attenuation (< 10 HU) 
on unenhanced CT. Furthermore, they display rapid washout of contrast medium (e.g. more 
than 50% after 10 minutes) (see figure 1) (Androulakis et al. 2011).   
 
 
 
 
 
Fig. 1. Washout sequence of an adrenocortical adenoma 
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In patients with non-functioning ACA, size of the adrenal mass is the major determinant 
in choice of management (Nieman 2010; Androulakis et al. 2011). Over 60% of 
incidentalomas less than 4 cm in diameter are ACA, in contrast only 2% are malignant. 
For a small non-functioning adenoma surgical resection is not necessary, follow-up 
through CT-imaging and biochemical screening will suffice. In lesions larger than 6 cm 
the prevalence of ACC increases to approximately 25% and surgery is indicated (Singh & 
Buch 2008). Management of adrenal masses with a diameter between 4 to 6 cm is less well 
defined. Because of a higher risk of malignancy in this subgroup of patients, surgical 
approach is recommended in most cases.  
In about 20% of adrenal adenomas hormonal work-up reveals overproduction of 
aldosterone (0.5-1%) or cortisol (5-20%), which may have a negative influence on patient’s 
health. Primary hyperaldosteronism is associated with increased risk of cardiovascular 
events. Additionally, patients with SCS may be at risk for potential morbidity attributable to 
cortisol overproduction. However, progression to clinical overt Cushing’s syndrome is 
uncommon. Surgical resection is considered the treatment of choice when biochemical 
overproduction is confirmed.  
3.2 Suspect pheochromocytoma  
It is essential to exclude a pheochromocytoma in patients presenting with an adrenal 
incidentaloma, because they are potentially lethal even when clinically asymptomatic 
(Young, Jr. 2007). Increased metanephrines and catecholamines in 24-hour urine specimen 
or fractionated plasma free metanaphrines in combination with features on CT, such as 
increased attenuation on unenhanced CT (>10 HU), prominent vascularity of the mass and 
delayed washout of contrast (<50% after 10 minutes), are highly suggestive of a 
pheochromocytoma (Terzolo et al. 2009). Characteristics indicative of pheochromocytoma 
on MRI include hyperintensity on T2-weighted imaging, with approximately 92% sensitivity 
and 88% specificity (Androulakis et al. 2011). When a pheochromocytoma is suspected, 
surgical treatment is indicated. Patients should be adequately prepared pre-operatively by 
adrenergic blockade, to prevent a perioperative hypertensive crisis caused by manipulation 
of the tumor and subsequent catecholamine-release. 
3.3 Suspect malignancy  
3.3.1 Adrenocortical carcinoma 
The risk of a malignancy is the main concern in patients with an incidentaloma. The 
prevalence of ACC in these patients without a history of malignancy is estimated at 4.8%, 
which makes it the most commonly identified adrenal malignancy (Terzolo et al. 2009). It is 
an aggressive malignancy with a median survival of 19 months (range 8-29 months), as 
calculated from data of 191 patients diagnosed between 2000 and 2010 in The Netherlands. 
Prognosis of ACC is still mainly dependent on stage at diagnosis (Fassnacht & Allolio 2009). 
For that reason it is vital to make accurate decisions regarding the necessary diagnostic and 
therapeutic measurements.  
A smaller tumor size corresponds with a lower tumor stage and consequently better 
prognosis. The risk of ACC is, as mentioned, associated with mass size. However, because the 
prevalence of adrenal adenoma is age-dependent, the presence of small adrenal masses in 
young patients should raise major concern of a potential malignancy. A malignant adrenal 
lesion typically presents as a larger mass (> 6 cm) and is characterized by an irregular border, 
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high attenuation on unenhanced CT (> 10 HU) and slow washout after contrast administration 
(see figure 2) (Terzolo et al. 2009). Own observations from the authors show that although an 
ACC may appear clinically non-functioning, in about 80-95% additional hormonal work-up 
and urinary steroid profiling reveals presence of hormone excess.  
When an adrenal malignancy is suspected, further investigation concerning cancer staging is 
warranted before directing the patient to surgery.  
 
 
Fig. 2. Washout sequence of an adrenocortical carcinoma 
3.3.2 Metastasis 
Tumors that frequently metastasize to adrenal glands include carcinomas of lungs, 
esophagus, kidney, colon, breast, liver, pancreas and stomach (Young, Jr. 2007). Metastases 
frequently occur bilateral and are variable in size, mostly smaller than 3 cm. Abdominal 
imaging may also reveal the presence of necrosis, hemorrhage or calcifications (Young, Jr. 
2000). Adrenal metastasis may cause beginning adrenal insufficiency. The suspicion of 
metastasis in an incidentaloma has clinical implications for prognosis and management and 
the search for a primary neoplasm is indicated. Resection of an isolated adrenal metastasis is 
associated with improved (disease-free and overall) survival. However, only in a limited 
number of cases adequate treatment of adrenal metastasis is possible (Terzolo et al. 2009).  
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PPAC/PRA ratio = plasma aldosterone concentration to plasma renin activity ratio.  
HU = Hounsfield Units. SCS = Subclinical Cushing’s Syndrome.  
Fig. 3. Algorithm for diagnostic evaluation of adrenal incidentaloma 
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4. Surgical treatment of incidentaloma 
Based on results of the diagnostic evaluation of the adrenal incidentaloma, decisions are 
made regarding the required therapeutic approach. However, a prospective randomized 
comparison of laparoscopic versus open adrenalectomy has not yet been performed. 
Recommendations are made based on little known evidence and pragmatism. 
4.1 Adenoma 
When an adrenocortical adenoma is suspected, subsequent management is founded on size 
of the mass and functionality. As mentioned, in case of overproduction of cortisol, 
aldosterone or sex hormones, surgical  resection of the mass is the treatment of choice. 
Mortality associated with adrenalectomy is estimated at less than 2% (Grumbach et al. 2003). 
Laparoscopic approach allows for a minimal invasive procedure associated with less 
morbidity in the patient and shorter period of hospitalization, while surgical results are 
comparable if performed by an experienced surgical team (Gill 2001). An important issue in 
resection of functioning adrenal masses is steroid suppletion peri- and postoperatively, 
because of the risk of adrenal insufficiency, hemodynamic crisis and death. In most cases 
this can be tapered over time.  
It is common practice to perform a surgical resection of incidentalomas larger then 6 cm, 
even if they are non-functioning and there are no signs of malignancy. It is unclear whether 
this is a good indication for a surgical resection, as follow-up might be sufficient as well. In 
lesions smaller than 4 cm, surgical resection is deemed not necessary and follow-up is 
generally accepted as the correct management. For lesions between 4 cm and 6 cm in 
diameter, a clear recommendation is lacking. In this group, surgery might be the safest 
option regarding the increasing risk of malignancy, however the number needed to treat 
with respect to curing a carcinoma will be large. The other option is to repeat medical 
imaging on a shorter term, for example 3 months. We expect urinary steroid profiling to 
become a valuable instrument in differentiating between benign and malignant lesions in 
this particular subgroup. 
4.2 Pheochromocytoma 
In patients with an adrenal incidentaloma and suspicion of a pheochromocytoma, rapid 
surgical resection is the standard curative option, associated with an excellent prognosis 
(Terzolo et al. 2009). Due to potential perioperative catecholamine excess, removal of a 
pheochromocytoma is accompanied with unusual hemodynamic and technical conditions, 
which require thorough preoperative medical preparation and adrenergic blockade to 
minimize perioperative cardiovascular morbidity. Furthermore, close perioperative 
monitoring is mandatory (Gill 2001; Ichikawa et al. 2002). Catecholamine release is 
suggested to be lower during laparoscopy than open adrenalectomy. Therefore, and because 
of the other benefits of laparoscopic surgery mentioned earlier, a laparoscopic approach is 
recommended in patients with an incidentaloma suspected for a pheochromocytoma (Cheah 
et al. 2002; Matsuda et al. 2002).  
4.3 Adrenocortical carcinoma 
A radical surgical resection is the only chance of cure for patients with an adrenocortical 
carcinoma, so an aggressive surgical approach is warranted (Dackiw et al. 2001; Miller et al. 
2010). A complete resection is possible in most cases when the diagnosis is suspected pre-
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operatively. Success rates drop significantly in cases where a carcinoma is not recognized 
before or during surgery, as follows from own observations from the authors. This 
emphasizes the need of a complete diagnostic work-up before the patient is directed for a 
surgical resection of an incidentaloma. The surgeon has to be prepared to perform an 
extensive resection and to keep the tumour capsule intact, as tumour spill is strongly 
associated with the occurrence of peritoneal carcinomatosis and a poor prognosis (Dackiw et 
al. 2001; Schteingart et al. 2005). Therefore, several authors recommend an open surgical 
approach instead of a laparoscopic technique, which is being used increasingly in adrenal 
surgery (Gonzalez et al. 2005; Zografos et al. 2009; Leboulleux et al. 2010; Miller et al. 2010). 
This topic is controversial, as prospective studies are lacking and retrospective studies show 
contradictory results. It is our belief that in general, a laparotomy is the safest option with 
respect to achieving a complete resection, although an expert surgeon in laparoscopic 
adrenalectomies might achieve better results than a less experienced surgeon can achieve 
performing a laparotomy. 
We therefore recommend that these patients should be treated by a multidisciplinary team 
with at least an endocrinologist, a surgeon, an oncologist, a pathologist and an experienced 
radiologist. The team should evaluate all patients with a suspect adrenal incidentaloma and 
decide on which patients will be treated surgically. Peri-operative hydrocortisone 
suppletion is recommended in all patients. The surgical technique should be determined 
with respect to the preference and specific qualities of the surgeon. The pathological 
examination of the tumour requires special attention, as carcinomas might be difficult to 
recognize. Rating systems as the Weiss-score and the Van Slooten score should be applied to 
all adrenal tumours. Close follow-up using medical imaging is strongly recommended as 
the risk of recurrence is high, even after complete resection. The debate regarding adjuvant 
therapy with mitotane is still ongoing, but it is the opinion of the authors that this is 
recommended if the tumor has a ki-67 index >10% (Terzolo et al. 2007). 
5. Follow-up of nonfunctioning adenoma 
A much discussed matter in the management of patients with an non-functioning adrenal 
adenoma is the frequency and duration of follow-up evaluation. Recommendations regarding 
follow-up are aimed at identifying changes in size or functionality of the adrenal adenoma and 
to recognize lesions with malignant potential that have escaped detection on primary analysis. 
Research suggests that approximately 8% of non-functional adrenal incidentalomas increase in 
size by at least 1 cm during follow-up, whereas 3-4% decrease in size (Singh and Buch 2008, 
Young, Jr. 2000). The majority of adrenal adenomas remain stable. In contrast, adrenocortical 
carcinomas usually display rapid growth. It is recommended to repeat adrenal imaging by CT-
scan in patients with nonfunctioning adenomas smaller than 4 cm within 6-12 months after the 
initial discovery to detect size changes (Grumbach et al. 2003).  
Approximately 20% of adrenal adenomas which displayed no excess hormone secretion at 
time of discovery, become autonomous during subsequent period of 4 years. Lesions of at 
least 3 cm in diameter are more likely to develop subclinical hyperfunction in contrast to 
smaller tumors (Androulakis et al. 2011). It is reported that the risk seems to disappear after 
3-4 years follow-up. Hyperaldosteronism or catecholamine hypersecretion occurs rarely 
during follow-up (Grumbach et al. 2003). Cortisol overproduction is more likely to occur. 
Hence, annual repetition of hormonal work-up, including late-night salivary cortisol and/or 
overnight dexamethasone (1 mg) suppression test is recommended during 4 years of follow-
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up. Whether measurement of PAC/PRA ratio and determination of fractionated 
metanephrines and catecholamines in 24-hour urine specimen or fractionated plasma free 
metanephrines should be repeated, is left to the discretion of the clinician as the indication 
may vary per patient.   
Further follow-up is not indicated in patients with an adrenal mass that remains stable on 
two imaging studies, done at least 6 months apart and do not demonstrate hormonal 
overproduction during 4 years of follow-up (Grumbach et al. 2003). Recommendations 
regarding follow-up of patients with a functional adenoma who are surgically treated, have 
not been developed.  
 
Suspicion  Management Considerations  
Adenoma    
Functioning  Laparoscopic resection  
Post-operative steroid 
hormone suppletion 
Nonfunctioning    
< 4 cm 
Follow-up  
- CT-scan within 6-12 months 
- Hormonal work-up annually 
during 4 years 
 
4-6 cm 
Risk group: 
- Repeat CT-scan within 6 months 
- Consider surgical resection  
- Urinary steroid profiling  
- Consider referral to specialized 
centre 
Suspicious imaging 
phenotype: open 
adrenalectomy 
> 6 cm Laparoscopic resection   
Pheochromocytoma  Laparoscopic resection Pre-operative preparation  
Adrenocortical 
carcinoma 
Referral to specialized centre 
Open adrenalectomy by specialized 
surgical team  
Post-operative steroid 
hormone suppletion 
Additional treatment 
depending on stage  
Fig. 4. Recommendations for management of adrenal incidentaloma 
6. Treatment in advanced stages 
6.1 Introduction 
The occurrence of metastatic disease in patients with adrenocortical carcinoma is not rare, as 
35% of patients present with stage 4 disease. 50% of patients who initially have had a 
curative resection, ultimately suffer a recurrence (Pommier & Brennan 1992; Stojadinovic et 
al. 2002). Even in advanced stages, a surgical debulking should be considered as our own 
observations indicate this might give a survival benefit. The backbone of treatment in 
advanced stages is formed by drug therapy with mitotane. Cytotoxic chemotherapy may be 
added, but response percentages vary. The role of radiation therapy remains disputed. 
Current experimental treatments include IGF-R blockers (OSI-906) and sunitinib. 
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6.2 Surgery 
In their recent review article, Fassnacht and Allolio provide a flowchart for management of 
ACC, which advocates at least consideration of surgery in every stage of disease (Fassnacht 
& Allolio 2009). Surgery including metastasectomy should at least be considered in stage IV 
patients and should be pursued if technically feasible and if the patient is motivated and in 
appropriate physical condition. On the other hand, the absolute survival gain might not 
weigh up against morbidity after surgery in certain (older) patients. This implies that the 
decision to perform surgery should be tailored to individual cases and should be discussed 
in a multidisciplinary team including an experienced surgeon. An additional benefit in cases 
of hormonal overproduction is that surgery might help controlling hormonal excess 
(Fassnacht & Allolio 2009).  
Repeat surgery should be considered individually, results indicate that this could be 
beneficial with regard to survival, especially if the interval between the two operations is 
more than 6 months (Allolio & Fassnacht 2006; Veytsman et al. 2009). 
6.3 Mitotane 
Mitotane is the only adrenal-specific agent available for the treatment of ACC (Haak et al. 
1994). The exact mechanism of action is not known, but it is proposed and generally 
accepted that mitotane is metabolized in adrenal mitochondria and causes cytotoxicity by 
oxidative damage through the production of free radicals (Veytsman et al. 2009). Whatever 
the exact pathway may be, the main effect is focal degeneration of the fascicular and 
(particularly) the reticular zone, which clinically leads to adrenal insufficiency for which 
glucocorticoid substitution is needed. (Hahner & Fassnacht 2005). 
When describing results of mitotane, one should differentiate between antitumor- and 
antihormonal effects. Regarding antitumor activity, mitotane has been assessed in several 
clinical studies, with variable results. Most studies were retrospective and comprised only 
small numbers of patients. Results show that mitotane does have activity against ACC. 
Percentages vary, but most investigators report total or partial tumor responses in about 
25% to 30% of cases.  
Concerning hormone excess, therapy with mitotane is sufficient in the majority of patients. 
However, the onset of mitotane is slow due to its lipophilic properties and the resulting 
accumulation in adipose tissues. It can take up to three months before therapeutic levels are 
established, so in patients with severe hypercortisolism another agent must be used 
concurrently to treat this condition while mitotane levels are being built up. The 
recommended treatment in this situation would be ketoconazol, which is generally well 
tolerated. Other options, dependent on the case at hand, could be etomidate, mifeprestone 
or metyrapone (Igaz et al. 2008; Veytsman et al. 2009). 
Mitotane treatment with a plasma concentration >14mg/L is associated with prolonged 
survival (Haak et al. 1994). Adverse effects occur in over 80% of patients and involve mainly 
the gastro-intestinal tract: anorexia, nausea, vomiting and diarrhea are frequently observed 
(Hahner & Fassnacht 2005).  Reported symptoms caused by effects on the central nervous 
system are ataxia, speed disturbances, confusion and somnolence. Typically, all adverse 
effects are reversible after mitotane withdrawal (Lanser et al. 1992). 
It is important to bear in mind that mitotane not only has adrenolytic effects, impairing 
adrenal steroidogenesis and thus inducing a need for replacement hydrocortisone, but also 
stimulates peripheral cortisol metabolism, so that hydrocortisone should be administered in 
higher doses. A second issue in managing patients on mitotane is monitoring thyroid 
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hormone and thyroid stimulating hormone levels, as mitotane can decrease thyroid 
hormone as well.  A third and possibly favorable interaction is the supposedly increased 
efficacy of cytotoxic chemotherapy when combined with mitotane. However, evidence on 
this topic is not conclusive. The proposed mechanism for this synergistic effect is the 
possible negative effect of mitotane on multidrug resistance proteins, as investigated in 
vitro, which could decrease the resistance of adrenocortical cancer cells to cytotoxic agents 
(Hahner & Fassnacht 2005; Igaz et al. 2008). 
Given the rarity of the indication and use of mitotane, it is recommended to leave treatment 
with mitotane to experienced doctors who are familiar with possible adverse events and are 
able to manage them. 
6.4 Cytotoxic chemotherapy 
Regarding cytotoxic chemotherapy, several combinations of agents have been tried so far. 
The highest response rates have been found in a trial with a treatment regimen combining 
mitotane with etoposide, doxorubicine and cisplatin (response rate 49%) and another trial 
with a treatment regimen combining mitotane and streptozotocine (response rate 36%) 
(Berruti et al. 2005), (Khan et al. 2000). Recently, these two regimens were compared in the 
First International Trial in Locally Advanced and Metastatic Adrenocortical Cancer (FIRM-
ACT). Results of this trial are expected in 2011. 
6.5 Radiation therapy 
Whether there is a place for radiation therapy in the treatment of adrenocortical carcinoma, 
is not yet clear according to the literature. Some authors claim to have accomplished 
favorable results, like prevention of local recurrence and adequate pain relief in metastatic 
disease, whereas toxicity was low (Fassnacht et al. 2006; Polat et al. 2009; Hermsen et al. 
2010).  
Other investigators recommend a more conservative approach, seeing that re-operations 
in a post-radiation tumor bed would be more difficult and that the favorable results are 
not all too convincing, given the retrospective character of research so far (Veytsman et al. 
2009). One could argue that radiation therapy can be of use in a palliative setting, 
especially in alleviating pain or neurologic complaints caused by metastatic disease in 
bone or brain and that a prospective trial is needed to determine the efficacy in an 
adjuvant setting. 
6.6 Future therapeutic agents 
The insulin-like growth factor receptor (IGF-R) in adrenocortical carcinoma is regarded as a 
possible target for treatment. Both antibody and tyrosine kinase inhibitor trials targeted 
against IGF-R are in progress. A trial using sunitinib as therapeutic agent produced 
disappointing results, but a better understanding of the metabolic complexity of the disease 
might lead to better trials in the future. Other areas of interest are VEGFR inhibitors and 
FGFR inhibitors, but these have not been translated into clinical trials yet.  
7. Limitations 
Due to limited evidence and guidelines, there are still multiple unresolved issues 
regarding management of incidentalomas, mainly concerning the duration of follow-up. 
The most important health risk in patients with an incidentaloma is related to several 
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characteristics of the adrenal mass associated with a malignant mass or 
pheochromocytoma (Kievit & Haak 2000). The rate of growth of a benign adrenal lesion 
remains unclear. Besides this, the percentage of patients that will develop hormonal 
overproduction when initial analysis was negative is uncertain as well. Furthermore, 
there is some concern regarding the side effects of repeated CT imaging. One report 
estimated the risk of fatal cancer due to exposure to ionising radiation during CT-imaging 
to be one in 430-2170 (Androulakis et al. 2011). This is comparable to the chance of 
developing an adrenocortical carcinoma during 3-year follow-up of an incidentaloma. 
Additionally, a long follow-up period with repeated extensive hormonal work-up and 
radiological imaging is associated with high costs. Since the frequency of discovered 
adrenal incidentalomas is expected to increase and the use of abdominal imaging is also 
increasing, the cost-effectiveness of repeated hormonal work-up and imaging becomes an 
important issue in health care. However, in practice, choices of follow-up or treatment are 
also based on psychological or social mechanisms, such as anxiety, doubt and risk 
aversion as well as cost-effectiveness. To elucidate these uncertainties prospective trials 
are warranted to evaluate the optimal diagnostic approach and management of an 
incidentaloma and provide an answer for unresolved questions.  
8. Organization of care 
The rarity of a number of adrenal disorders, such as ACC or pheochromocytoma, and the 
dismal prognosis associated with an adrenal malignancy, requires a multidisciplinary 
approach of each patient. In the event of an ACC, physicians often are not familiar with the 
disorder and its few available treatment options, resulting in inferior patient care. Given that 
a large part of diagnostics and management is based on pragmatism and expert opinion 
instead of prospective trials, additional studies concerning treatment and follow-up of 
adrenal tumors are necessary. In order to improve care in patients with adrenal disorders 
and stimulate scientific research, national and international collaboration is vital. In a 
number of European countries (France, Germany, Italy, The Netherlands), national 
networks have been set up to coordinate adrenal diseases-research and - patient care. 
(Koschker et al. 2006; van Ditzhuijsen et al. 2007)  
In the southern region of The Netherlands, our hospital acts as a tertiary referral center for 
patients with adrenal tumors. We have provided local hospitals with a guideline for 
diagnostics and patient referral similar to the procedure described in this chapter. The 
subsequent centralization of these patients facilitates reliable pre-operative diagnostics and 
specialized surgery, of which the importance cannot be overemphasized. Too many patients 
each year see their chance of survival be ruined because an adrenal malignancy is not 
recognized before, during or even after surgery. Irradical resection and/or rupture of the 
tumor capsule in adrenocortical carcinoma is fatal without exception, but can often be 
prevented if treated by experienced doctors.  
Therefore, we strongly support initiatives of centralization being deployed in other regions 
and countries, as the beneficial effects of specialization have been proven multiple times in 
other rare diseases (Sosa et al. 1998; Kumar et al. 2001). Centralization and multidisciplinary 
approach is associated with more complete resections, improved survival and enhanced 
patient care. A secondary benefit is the facilitation of scientific research and participation in 
clinical trials in centralized populations of patients with a rare disease. 
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9. Conclusion 
Due to the increasing discovery of adrenal incidentalomas, the diagnostic work-up as well 
as the management of incidentalomas is a growing public health challenge. Hormonal 
functionality and malignant potential of the lesion need to be evaluated. Incidentalomas are 
mostly benign nonhypersecretory adrenal adenomas, however important diagnoses to 
exclude are (subclinical) Cushing’s Syndrome, primary aldosteronism, sex hormone 
overproduction, pheochromocytoma or malignancy (e.g. adrenocortical carcinoma, 
metastasis). Surgical treatment is recommended in all patients with a hormonally active 
tumor or a tumor larger than 6 cm. Furthermore, surgery may be indicated in individual 
cases depending on radiological characteristics. In patients with nonfunctioning adrenal 
adenomas smaller than 4 cm follow-up with CT-scan after 6-12 months and annual 
hormonal work-up for 4 years is recommended. An adrenocortical carcinoma is rare, but 
often lethal. Surgery is the cornerstone of initial treatment, whereas drug therapy with 
mitotane is inevitable in advanced stages. It is recommended that patients with adrenal 
disorders are treated in a multidisciplinary setting by experienced physicians. Centralization 
of care is strongly encouraged in order to improve patient outcome and to stimulate 
research and trial participation. 
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